Literature DB >> 3608105

Relation of arterial blood lactate to oxygen delivery and hemodynamic variables in human shock states.

A B Groeneveld, A D Kester, J J Nauta, L G Thijs.   

Abstract

A retrospective study of 50 patients with circulatory shock and serial hemodynamic and metabolic measurements was undertaken. From the patient records, values for first measured cardiac index (CI) (t = 1) and highest CI (t = 2) with concomitantly obtained hemodynamic and metabolic variables and with arterial blood lactate levels (ABL), measured within 1.5 hours of t = 1 and t = 2 were taken. Nineteen patients had nonseptic shock (NSS), and 31 had septic shock (SS). Mortality rates were equivalent. At both t = 1 and t = 2, CI and O2 delivery (DO2) were higher and systemic vascular resistance index (SVRI) was lower in SS than in NSS. Although increases in DO2 were significant and not different between the groups and initial ABL values were similar, ABL had declined 50% in NSS but had not changed in SS (p less than 0.0001). From the hemodynamic and metabolic variables investigated in NSS, changes in ABL only correlated with changes in arterial oxygen content (CaO2; r = -0.65; p less than 0.01). Changes in ABL did not correlate with changes in DO2 in both groups. In SS, changes in ABL best correlated with changes in SVRI (r = -0.54; p less than 0.01). Our data suggest that anaerobic metabolism, reflected by ABL, decreases in response to an increase in CaO2, CI, and thus DO2 in NSS but not in hyperdynamic SS. Anaerobic metabolism in the latter may relate to peripheral vasodilation, associated with peripheral "functional" shunting of blood transported oxygen, rather than to insufficient DO2.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3608105

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  11 in total

1.  Lactate: may I have your votes please?

Authors:  J Bakker
Journal:  Intensive Care Med       Date:  2001-01       Impact factor: 17.440

Review 2.  European Society of Intensive Care Medicine. Expert panel: the use of the pulmonary artery catheter.

Authors: 
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

3.  Plasma lipid peroxides and antioxidants in human septic shock.

Authors:  A C Ogilvie; A B Groeneveld; J P Straub; L G Thijs
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 4.  The haemodynamics of septic shock.

Authors:  L G Thijs; A J Schneider; A B Groeneveld
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

5.  Muscle lactate concentration during experimental hemorrhagic shock.

Authors:  Myun Yang
Journal:  J Anesth       Date:  1998-06       Impact factor: 2.078

6.  Effect of N-acetylcysteine and fructose-1,6-bisphosphate in the treatment of experimental sepsis.

Authors:  Ricardo Obalski de Mello; Adroaldo Lunardelli; Eduardo Caberlon; Cristina Machado Bragança de Moraes; Roberto Christ Vianna Santos; Vinicius Lorini da Costa; Gabriela Viegas da Silva; Patrícia da Silva Scherer; Luiz Eduardo Coimbra Buaes; Denizar Alberto da Silva Melo; Márcio Vinícius Fagundes Donadio; Fernanda Bordignon Nunes; Jarbas Rodrigues de Oliveira
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

7.  Prognostic values of serum cytokines in septic shock.

Authors:  C Martin; P Saux; J L Mege; G Perrin; L Papazian; F Gouin
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

8.  Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock.

Authors:  G Bernardin; C Pradier; F Tiger; P Deloffre; M Mattei
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

9.  Splanchnic metabolism associated with liver metastasis.

Authors:  M S Dahn; M P Lange; M A Kosir
Journal:  Intensive Care Med       Date:  1995-04       Impact factor: 17.440

10.  Lactate concentration gradient from right atrium to pulmonary artery: a commentary.

Authors:  Jacques Creteur
Journal:  Crit Care       Date:  2005-07-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.